Intelligence / Healthtech / New Clinical Trials / F2G Ltd
Clinicaltrial registered26 Oct 2026
F2G Ltd
26 Oct 2026: Trial registered · Managed Access Program Allowing Access to Olorofim. Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 26 Oct 2026
- Title
- Managed Access Program Allowing Access to Olorofim
- Study Type
- Expanded Access
- Status
- Available
- Reference
- NCT07895264
What this signal means
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS
Find the decision makers at F2G Ltd
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.